Company: REVB
Filing Date: 2025-04-04
Form Type: DRS
Source: 0001213900-25-029022
Chunk: 76

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-04-04
Form: DRS
Chunk 76
---
 restrictive covenants we may agree to in connection therewith. 44

CAPITALIZATION The following table sets forth our cash and cash equivalents, debt obligations, and capitalization as of December 31, 2024 (i) on an actual basis, adjusted for the effect of the reverse stock split; and (ii) on a pro forma as adjusted basis to give effect to the issuance and sale of shares of our common stock and Common Stock Warrants based on an assumed public offering price, based on the last reported sale price on April [•], 2025 (adjusted to give effect to the reverse stock split), of $ per share, for total net proceeds of approximately $ (assuming no sale of pre -fundedwarrants).

|                                                                                                                                                             |     | As of December 31, 2024 |             |   |     |           |
|:------------------------------------------------------------------------------------------------------------------------------------------------------------|:----|:------------------------|------------:|:--|:----|:----------|
|                                                                                                                                                             |     | Actual                  |             |   |     | Pro Forma |
| Cash and cash equivalents                                                                                                                                   |     | $                       |   6,499,018 |   |     | $         |
| Stockholders’ equity:                                                                                                                                       |     |                         |             |   |     |           |
| Common Stock, $0.001 par value, 500,000,000 shares authorized; 522,223 shares issued and outstanding actual; shares issued and shares outstanding pro forma |     | $                       |         522 |   |     | $         |
| Additional paid-in capital                                                                                                                                  |     | $                       |  45,213,498 |   |     | $         |
| Accumulated deficit                                                                                                                                         |     | $                       | (40,505,638 | ) |     | $         |
| Total stockholders’ equity (deficit)                                                                                                                        |     | $                       |   4,708,382 |   |     | $         |
| Total capitalization                                                                                                                                        |     | $                       |   4,708,382 |   |     | $         |

The foregoing pro forma as adjusted information is illustrative only, and our capitalization following the completion of this offering will be adjusted based on the actual public offering price and other terms of this offering determined at pricing. You should read this table together with our financial statements and the related notes appearing elsewhere in this prospectus and “Management’s discussion and analysis of financial condition and results of operations